Table 3.
Nonserious events and patients with event throughout the whole observation period according to treatment group
| Type of event | Rtx, n=100 | St-Cp, n=103 |
|---|---|---|
| Myelotoxicity | ||
| Pancytopenia | 0 | 1 |
| Leukopenia and anemia | 0 | 5 |
| Anemia | 0 | 11a |
| Leukopenia | 0 | 35b |
| Thrombocytopenia | 0 | 7c |
| Total | 0 | 59b |
| Minor cardiovascular disease | 3 | 0 |
| Infections | ||
| Respiratory tract | 4 | 15b |
| Urinary tract | 0 | 1 |
| Herpes zoster | 0 | 7c |
| Other/unspecified | 3 | 14a |
| Total | 7 | 37b |
| Infusion reactionsd | 28 | 0b |
| Other events | 8 | 11 |
| Liver toxicity | 1 | 7 |
| Hyperglycemia | 2 | 10c |
| Total | 3 | 28b |
| Total no. of nonserious events | 52 | 127 |
| Patients with nonserious eventse | 41 | 58 |
a
P<0.001 according to the Fisher exact test, St-Cp versus Rtx.
b
P<0.01 according to the Fisher exact test, St-Cp versus Rtx.
c
P<0.05 according to the Fisher exact test, St-Cp versus Rtx.
d
Bronchial wheezing, dyspnea, rash, erythema, itching, rhinorrhea, and hypotension.
e
One patient may have more than one event.